276 related articles for article (PubMed ID: 22100573)
1. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.
Hermos JA; Young MM; Fonda JR; Gagnon DR; Fiore LD; Lawler EV
Clin Infect Dis; 2012 Jan; 54(1):33-42. PubMed ID: 22100573
[TBL] [Abstract][Full Text] [Related]
2. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs.
Eurich DT; Sadowski CA; Simpson SH; Marrie TJ; Majumdar SR
Am J Med; 2010 Jan; 123(1):47-53. PubMed ID: 20102991
[TBL] [Abstract][Full Text] [Related]
3. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis.
Giuliano C; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2012 May; 5(3):337-44. PubMed ID: 22697595
[TBL] [Abstract][Full Text] [Related]
4. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia.
Meijvis SC; Cornips MC; Voorn GP; Souverein PC; Endeman H; Biesma DH; Leufkens HG; van de Garde EM
Eur Respir J; 2011 Nov; 38(5):1165-72. PubMed ID: 21478217
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia.
de Jager CP; Wever PC; Gemen EF; van Oijen MG; van Gageldonk-Lafeber AB; Siersema PD; Kusters GC; Laheij RJ
Aliment Pharmacol Ther; 2012 Nov; 36(10):941-9. PubMed ID: 23034135
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
[TBL] [Abstract][Full Text] [Related]
7. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.
Gulmez SE; Holm A; Frederiksen H; Jensen TG; Pedersen C; Hallas J
Arch Intern Med; 2007 May; 167(9):950-5. PubMed ID: 17502537
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor discontinuation in long-term care.
Linsky A; Hermos JA; Lawler EV; Rudolph JL
J Am Geriatr Soc; 2011 Sep; 59(9):1658-64. PubMed ID: 21883102
[TBL] [Abstract][Full Text] [Related]
9. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.
Bajaj JS; Zadvornova Y; Heuman DM; Hafeezullah M; Hoffmann RG; Sanyal AJ; Saeian K
Am J Gastroenterol; 2009 May; 104(5):1130-4. PubMed ID: 19337238
[TBL] [Abstract][Full Text] [Related]
10. Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting.
Oudit GY; Bakal JA; McAlister FA; Ezekowitz JA
Eur J Heart Fail; 2011 Nov; 13(11):1211-5. PubMed ID: 21831912
[TBL] [Abstract][Full Text] [Related]
11. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
Stevens V; Dumyati G; Brown J; Wijngaarden E
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia.
Johnstone J; Nerenberg K; Loeb M
Aliment Pharmacol Ther; 2010 Jun; 31(11):1165-77. PubMed ID: 20222914
[TBL] [Abstract][Full Text] [Related]
13. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study.
Othman F; Crooks CJ; Card TR
BMJ; 2016 Nov; 355():i5813. PubMed ID: 28715344
[No Abstract] [Full Text] [Related]
14. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
Stockl KM; Le L; Zakharyan A; Harada AS; Solow BK; Addiego JE; Ramsey S
Arch Intern Med; 2010 Apr; 170(8):704-10. PubMed ID: 20421557
[TBL] [Abstract][Full Text] [Related]
15. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.
Banerjee S; Weideman RA; Weideman MW; Little BB; Kelly KC; Gunter JT; Tortorice KL; Shank M; Cryer B; Reilly RF; Rao SV; Kastrati A; de Lemos JA; Brilakis ES; Bhatt DL
Am J Cardiol; 2011 Mar; 107(6):871-8. PubMed ID: 21247527
[TBL] [Abstract][Full Text] [Related]
16. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia.
Jena AB; Sun E; Goldman DP
J Gen Intern Med; 2013 Feb; 28(2):223-30. PubMed ID: 22956446
[TBL] [Abstract][Full Text] [Related]
17. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
18. The natural history of community-acquired pneumonia in COPD patients: a population database analysis.
Müllerova H; Chigbo C; Hagan GW; Woodhead MA; Miravitlles M; Davis KJ; Wedzicha JA
Respir Med; 2012 Aug; 106(8):1124-33. PubMed ID: 22621820
[TBL] [Abstract][Full Text] [Related]
19. Proton-pump inhibitor use and the risk for community-acquired pneumonia.
Sarkar M; Hennessy S; Yang YX
Ann Intern Med; 2008 Sep; 149(6):391-8. PubMed ID: 18794558
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitors and Infant Pneumonia/Other Lower Respiratory Tract Infections: National Nested Case-control Study.
Blank ML; Parkin L; Zeng J; Barson D
J Pediatr Gastroenterol Nutr; 2018 Sep; 67(3):335-340. PubMed ID: 29601438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
